These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18201402)

  • 21. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.
    Gilham C; Sargent A; Peto J
    BJOG; 2020 Jan; 127(1):58-68. PubMed ID: 31541495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
    Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
    Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
    Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.
    Kitchener HC; Almonte M; Thomson C; Wheeler P; Sargent A; Stoykova B; Gilham C; Baysson H; Roberts C; Dowie R; Desai M; Mather J; Bailey A; Turner A; Moss S; Peto J
    Lancet Oncol; 2009 Jul; 10(7):672-82. PubMed ID: 19540162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme.
    Nygård JF; Sauer T; Nygård M; Skare GB; Thoresen SØ
    J Med Screen; 2004; 11(2):70-6. PubMed ID: 15153321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Three-year follow-up results of visual inspection with acetic acid/Lugol's iodine (VIA/VILI) used as an alternative screening method for cervical cancer in rural areas].
    Zhang YZ; Ma JF; Zhao FH; Xiang XE; Ma ZH; Shi YT; Hu SY; Qiao YL
    Chin J Cancer; 2010 Jan; 29(1):4-8. PubMed ID: 20038302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand.
    Deerasamee S; Srivatanakul P; Sriplung H; Nilvachararung S; Tansuwan U; Pitakpraiwan P; Kaewkungwal J; Singhasivanon P; Nimnakorn P; Sankaranarayanan R
    Asian Pac J Cancer Prev; 2007; 8(4):547-56. PubMed ID: 18260727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of colposcopy and treatment: data from the national survey of Italian organised cervical screening programmes.
    Volante R; Giubilato P; Ronco G
    Epidemiol Prev; 2007; 31(2-3 Suppl 2):61-8. PubMed ID: 17824363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of a national cervical screening programme in Ireland, CervicalCheck: the first 6 years.
    Flannelly GM; Mooney MT; Greehy GM; Keogh EB; McNally SA; Fitzpatrick PE
    Eur J Cancer Prev; 2018 Mar; 27(2):158-163. PubMed ID: 27824660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study.
    Canfell K; Barnabas R; Patnick J; Beral V
    Br J Cancer; 2004 Aug; 91(3):530-6. PubMed ID: 15266332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
    Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
    Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
    Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.
    Watson M; Soman A; Flagg EW; Unger E; Deapen D; Chen VW; Peres LC; Copeland G; Tucker TC; Garnett E; Saraiya M
    Prev Med; 2017 Oct; 103():60-65. PubMed ID: 28765084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.